Who are fluidotherapy with ringer-lactate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Enriched Ringer's lactate solution, Plasma-lyte, Ringer lactate (RL), Ringer-acetat, sodium bicarbonate Ringer's solution, Plasma-lyte (static group).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fluidotherapy-with-ringer-lactate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

fluidotherapy with ringer-lactate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

fluidotherapy with ringer-lactate (fluidotherapy with ringer-lactate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Crystalloid intravenous fluid. Area: Critical Care / Emergency Medicine / Perioperative Medicine.

marketed Crystalloid intravenous fluid Critical Care / Emergency Medicine / Perioperative Medicine Small molecule Live · refreshed every 30 min

Target snapshot

fluidotherapy with ringer-lactate (fluidotherapy with ringer-lactate) — Medical University of Vienna. Fluidotherapy with Ringer-lactate is an intravenous fluid replacement therapy that restores intravascular volume and electrolyte balance in dehydrated or hypovolemic patients.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
fluidotherapy with ringer-lactate TARGET	fluidotherapy with ringer-lactate	Medical University of Vienna	marketed	Crystalloid intravenous fluid
Enriched Ringer's lactate solution	Enriched Ringer's lactate solution	Scientific Institute San Raffaele	marketed	Crystalloid intravenous fluid
Plasma-lyte	Plasma-lyte	Fundación Santa Fe de Bogota	marketed	Crystalloid intravenous fluid / Electrolyte replacement solution
Ringer lactate (RL)	Ringer lactate (RL)	Fundación Cardioinfantil Instituto de Cardiología	marketed	Crystalloid intravenous fluid
Ringer-acetat	Ringer-acetat	Rigshospitalet, Denmark	marketed	Crystalloid intravenous fluid
sodium bicarbonate Ringer's solution	sodium bicarbonate Ringer's solution	The First Affiliated Hospital with Nanjing Medical University	marketed	Crystalloid intravenous fluid / electrolyte solution
Plasma-lyte (static group)	Plasma-lyte (static group)	Algemeen Ziekenhuis Maria Middelares	marketed	Crystalloid intravenous fluid / Electrolyte replacement solution

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Crystalloid intravenous fluid class)

Fayoum University Hospital · 1 drug in this class
Federal University of Juiz de Fora · 1 drug in this class
Fundación Cardioinfantil Instituto de Cardiología · 1 drug in this class
McGill University Health Centre/Research Institute of the McGill University Health Centre · 1 drug in this class
Medical University of Vienna · 1 drug in this class
Nationwide Children's Hospital · 1 drug in this class
Rigshospitalet, Denmark · 1 drug in this class
Scientific Institute San Raffaele · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). fluidotherapy with ringer-lactate — Competitive Intelligence Brief. https://druglandscape.com/ci/fluidotherapy-with-ringer-lactate. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing